Cognition Medical Corp. appears in FDA records as the applicant for a single 510(k) premarket notification, K253422, covering a device named OAB Delivery Catheter. The FDA record lists the applicant at an Atlanta, Georgia address and identifies the submission as a Traditional 510(k) reviewed by the cardiovascular advisory committee. The decision letter addresses correspondence through a regulatory affairs director at MCRA, LLC in Washington, DC. The device is classified as a percutaneous catheter, Class II, under 21 CFR 870.1250, with product code QJP. [1][2][7]
The K253422 filing and its scope
K253422 was received by FDA on October 1, 2025, and decided on October 2, 2026, with decision code SESE, described as Substantially Equivalent. The submission is a Traditional 510(k) with no third-party review indicated, and the record notes that a summary is available. The decision letter carries the same K number and dates the applicant's submission September 1, 2026. [1][2]
The decision letter lists the trade and device name as OAB Delivery Catheter, regulation number 21 CFR 870.1250, regulation name Percutaneous Catheter, regulatory Class II, and product codes QJP and DQY. The FDA database record for the same filing lists product code QJP and describes the openFDA device name as Catheter, Percutaneous, Neurovasculature, with device class 2 and regulation number 870.1250. [1][2]
The FDA record assigns the review to the cardiovascular advisory committee, with advisory committee code CV and description Cardiovascular. The same record carries a separate review advisory committee code, NE, without a spelled-out description in the available text. [1]
Packaging and testing references
The decision letter describes the OAB Delivery Catheter as placed in a dispenser hoop that is inserted into a pouch, with the pouch then placed inside a carton box. The letter also includes a section heading for testing. No test methods, acceptance criteria or results are stated in the available text. [2]
Applicant identity and published company material
The FDA record gives the applicant as Cognition Medical Corp. at 103 Calibre Woods Dr. NE, Atlanta, GA 30329, with a contact named Alex Turjman. The decision letter routes correspondence to Cognition Medical Corp. care of Robert Herrmann, Ph.D., Director, Neurointerventional Regulatory Affairs at MCRA, LLC, 803 7th Street NW, Washington, DC 20001. Filing addresses are not treated here as a verified headquarters. [1][2]
A website published under the Cognition Medical name describes a commitment to neurovascular devices for stroke patients and states that neurovascular is its first target market. The site lists an Atlanta address at 27 28th Street NW, Suite 4, 30309, which differs from the FDA filing address. No document in the available records links that website entity to the K253422 applicant, so the site statements are attributed to their publisher and not confirmed as the applicant's. [4]
Collection context
The linked FDA records for this applicant comprise one 510(k) entry, K253422, and the decision counts for that collection show one SESE decision. The smaller record sample likewise contains that single entry, dated October 2, 2026, with product code QJP. These counts describe the linked filings as of November 20, 2026, and are not measures of sales, total portfolio or safety performance. [1][5]
FDA's published list of 510(k) final decisions rendered since October 1, 2026, includes K253422 with a Substantially Equivalent decision, device name OAB Delivery Catheter and applicant Cognition Medical Corp., published October 2, 2026. No premarket approval, de novo or recall record for this applicant appears in the available records. [5][6]
